Adaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy Rating
TD Cowen analyst Marc Frahm has maintained their bullish stance on ADAP stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...
We have the technology to save thousands of lives, experts say, and we must start using it now
Australia is on the brink of a healthcare revolution driven by DNA science that will save lives and prevent disease – but top ...
STAT10h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Acrivon Therapeutics, Inc.: Promising Advancements and Strong Buy Rating Backed by Innovative Pipeline and Solid Financial Position
TD Cowen analyst Marc Frahm has maintained their bullish stance on ACRV stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...